Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...

Merck (NYSE:MRK) has broken ground on a $1 billion facility in Wilmington, Delaware, becoming the latest pharmaceutical ...

The drug maker on Tuesday announced a new 470,000-square-foot facility in Wilmington, Delaware, where it will make Keytruda, ...

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...

Mounting competition for Keytruda doesn't significantly alter Merck's long-term prospects. Even when equities are volatile, investors can find great stocks to buy. And the rules for investing in ...

Merck is expanding domestic manufacturing with a $895 million investment in its Kansas factory, one of several major projects ...